Lieping ChenImmunology expert，make remarkable contributions in the discovery of Programmed Death-1
Professor of Yale University School of Medicine
Director of the Department of oncology at Yale Cancer Center
Visiting fellow of Chinese Academy of Sciences
First breakthrough of the years by Science magazine 2013
William B. Coley Award
Title：
The PD-L1/PD-1 Blockade Therapy for Human Cancers
Abstract：Immune responses are tightly controlled by immune modulatory pathways which constitute various receptors and ligands and could positively or negatively influence the quality and even the direction of immune responses. The PD-1/PD-L1 immune modulatory pathway plays important roles in suppressing antigen-specific immune responses and inflammation. Selective expression of PD-L1 (B7-H1) in tumor microenvironment and subsequent interaction with PD-1 on tumor-infiltrating T cells is demonstrated to be a major mechanism of losing T cell immunity in tumor sites in a significant fraction of cancer patients. I will give a brief overview of current effort in clinical effort for the treatment of advanced human cancers and discuss principles and perspectives of anti-PD-1/PD-L1 therapy.